Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRM8 | O00222 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7565004 | 0.84 | CYP1A2 (0.47) | CYP1A2TSHRALDH1A1KMT2AMEN1 | |
| SCHEMBL17094769 | 0.82 | CYP1A2 (0.43) | CYP1A2TSHRALDH1A1KDM4EMAPT | |
| SCHEMBL13002941 | 0.81 | ALDH1A1 (0.42) | CYP1A2TSHRALDH1A1KAT2BCTSD | |
| SCHEMBL8078638 | 0.81 | ALDH1A1 (0.44) | CYP1A2TSHRALDH1A1KAT2BCTSD | |
| SCHEMBL9056707 | 0.79 | ALDH1A1 (0.45) | CYP1A2TSHRALDH1A1KAT2BCTSD | |
| SCHEMBL7533289 | 0.79 | ALDH1A1 (0.45) | CYP1A2TSHRALDH1A1KAT2BCTSD | |
| SCHEMBL12279667 | 0.79 | MAPT (0.38) | CYP1A2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL7877336 | 0.77 | CYP1A2 (0.55) | CYP1A2TSHRALDH1A1MAPTRAB9A | |
| SCHEMBL14735892 | 0.76 | CYP1A2 (0.61) | CYP1A2TSHRALDH1A1CTSDMAPT | |
| SCHEMBL14733944 | 0.75 | ALDH1A1 (0.55) | CYP1A2TSHRALDH1A1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002074176-A1 | METHODS FOR MODULATING NEURAL ACTIVITY IN THE RETINA | UNIVERSITY OF WASHINGTON (US) | 2002-09-26 | — | — | WO | claimed |
| US-7737169-B2 | Anionically substituted 7-nitroindoline derivatives and their uses | MEDICAL RESEARCH COUNCIL (GB) | 2010-06-15 | — | — | US | disclosed |
| US-20070203099-A1 | Anionically substituted 7-nitroindoline derivatives and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2007-08-30 | — | — | US | disclosed |
| US-20070203099-A1 | Anionically substituted 7-nitroindoline derivatives and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2007-08-30 | — | — | US | disclosed |
| EP-1757585-A1 | Anionically substituted 7-Nitroindoline derivatives and their uses | Medical Research Council (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-5635608-A | CONTAINS PHOTOREMOVABLE ALPHA-CARBOXY-SUBSTITUTED ORTHO-NITROBENZYL GROUP THAT CHANGES THE FLUORESCENCE AND BIOLOGICAL PROPERTIES OF THE COMPOUND | MOLECULAR PROBES, INC. (US) | 1997-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203099-A1 | Anionically substituted 7-nitroindoline derivatives and their uses | SLC18A3, SLC18A1, SLC18A2 | CYP1A2 2873/4885TSHR 1797/4885ALDH1A1 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.